Product Description
Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vincristine)
Mechanisms of Action: Mitosis Inhibitor,Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia
Known Adverse Events: Insomnia | Anemia | Febrile Neutropenia | Neutropenia | Constipation | Diarrhea
Company: Premier Inc
Company Location:
Company CEO:
Additonal Commercial Interests: Pfizer
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Kenya, Korea, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Zimbabwe
Active Clinical Trial Count: 43
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Brain Cancer|Breast Cancer|Diffuse Large B-Cell Lymphoma|Glioma|Hodgkin Lymphoma|Leukemia|Lymphoid Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Neuroblastoma|Non-Small-Cell Lung Cancer|Other|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Retinoblastoma|Sarcoma, Ewing|T-Cell Peripheral Lymphoma
Phase 2: AIDS-Related Lymphoma|B-Cell Leukemia|COVID-19|Fetal Diseases|Follicular Lymphoma|Large-Cell Immunoblastic Lymphoma|Leukemia, Plasma Cell|Plasmablastic Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Pregnancy Complications, Infectious|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RETINO2018 | P3 |
Recruiting |
Retinoblastoma |
2035-01-20 |
|
| HR-NBL2 | P3 |
Active, not recruiting |
Neuroblastoma |
2031-09-24 |
|
| iEuroEwing | P3 |
Recruiting |
Sarcoma, Ewing |
2031-05-31 |
|
| 2019-004153-93 | P3 |
Active, not recruiting |
Sarcoma, Ewing |
2030-12-17 |